

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 August 2009 (06.08.2009)

PCT

(10) International Publication Number
WO 2009/097287 A8

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/4375 (2006.01)

(21) International Application Number:

PCT/US2009/032148

(22) International Filing Date:

27 January 2009 (27.01.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/025,665 1 February 2008 (01.02.2008) US
61/053,091 14 May 2008 (14.05.2008) US

(71) Applicant (for all designated States except US): IRM LLC [US/US]; 131 Front Street, P.O. Box HM 2899, Hamilton, HM LX (BM).

(72) Inventors; and

(75) Inventors/Applicants (for US only): OKRAM, Barun [IN/US]; 9115 Judicial Drive, Unit #415 1, San Diego, California 92122 (US). **UNO, Tetsuo** [JP/US]; 4495 Shorepointe Way, San Diego, California 92130 (US). **DING, Qiang** [CN/US]; 9045 Judicial Drive, Apt. 1208, San Diego, California 92122 (US). **LIU, Yahua** [CN/US]; 7548 Charmant Drive, #1414, San Diego, California 92122 (US). **JIN, Yunho** [KR/US]; 13447 Tiverton Road, San Diego, California 92130 (US). **JIN, Qihui** [CN/US]; 4526 Vereda Mar De Ponderosa, San Diego, California 92130 (US). **WU, Xu** [CN/US]; 13154 Blue Lace Trail, San Diego, California 92130 (US). **CHE, Jianwei** [US/US]; 7188 Arroyo Grande Road, San Diego, California 92129 (US). **YAN, S. Frank** [CN/CN]; 396 Ling Zhao Road, No. 4, Room 402, Shanghai 200124 (CN). **HAO, Xueshi** [CN/US]; 3937 Nobel Drive, #135, San Diego, California 92122 (US).

(74) Agents: RAYMOND, Daniel E. et al; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the revised international search report:

1 October 2009

(48) Date of publication of this corrected version:

12 August 2010

(15) Information about Corrections:

see Notice of 12 August 2010

Previous Corrections:

see Notice of 14 January 2010

see Notice of 1 October 2009

(54) Title: COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

(57) Abstract: The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT*, c-Kit, RET, TrkA, TrkB, TrkC-GR-IR, Alk, c-FMS or combinations thereof.



WO 2009/097287 A8